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Abstract: Background: Percutaneous electrical stimulation and transcutaneous electrical stimulation
(PTNS and TTNS) of the posterior tibial nerve are internationally recognized treatment methods
that offer advantages in terms of treating patients with overactive bladder (OAB) who present with
urinary incontinence (UI). This article aims to analyze the scientific evidence for the treatment of
OAB with UI in adults using PTNS versus TTNS procedures in the posterior tibial nerve. Methods:
A systematic review was conducted, between February and May 2021 in the Web of Science and
Scopus databases, in accordance with the PRISMA recommendations. Results: The research identified
259 studies, 130 of which were selected and analyzed, with only 19 used according to the inclusion
requirements established. The greatest effectiveness, in reducing UI and in other parameters of
daily voiding and quality of life, was obtained by combining both techniques with other treatments,
pharmacological treatments, or exercise. Conclusions: TTNS has advantages over PTNS as it is more
comfortable for the patient even though there is equality of both therapies in the outcome variables.
More research studies are necessary in order to obtain clear scientific evidence.
Keywords: percutaneous electric nerve stimulation; transcutaneous electric nerve stimulation; adult;
urinary bladder; overactive; urinary incontinence; tibial nerve
1. Introduction
The International Classification of Diseases (ICD-11) defines overactive bladder syn-
drome (OAB), with code GC50.0, as a urological condition characterized by voiding ur-
gency, polyuria, and nocturia that may or may not be accompanied by urinary incontinence
(UI) [1]. OAB presents a worldwide prevalence [2] of 16% to 23%, rising to 15% in those
over the age of 40 years [3] and to 30–40% in those over 75 years [4], although it can be
found in people of all ages. Its prevalence in Europe [5] is around 12%.
J.C. Angulo, in an article [6] published in 2016, revealed a 19.46% prevalence of OAB
in the Spanish population, with at least one episode of urge UI (UUI) a day in 48.74% of
cases [6]. This prevalence is greater in females than in males. Studies conducted [7] in the
populations of Europe, the United States, Asia, and Africa reveal a prevalence of UUI of
1.5% to 14.3% in men aged between 18 and 20 years, whereas in women, it ranges from
1.6% to 22.8%. The same is true for those aged over 30 years, where the prevalence in men
is from 1.7% to 13.3%, as opposed to 7% to 30.3% in women [7].
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Among subjects with OAB on the global scale, UUI has been observed to be the most
unpleasant symptom of this condition [4]. Further, people with OAB usually adopt certain
coping strategies that involve a decrease in their quality of life and socialization, such as
limiting liquid intake, avoiding traveling, and attempting to have direct access to toilets [3].
UI is the involuntary leakage of urine and lack of ability to control urination, accompa-
nied by spontaneous contractions of the detrusor muscle. There are various subtypes of UI:
urgency UI (UII), the sudden desire or need to urinate; stress UI (SUI), caused by efforts,
physical exercise, sneezing, or coughing; mixed UI (MUI), combined with urgency and
efforts [1] (code MF50.2 in ICD-11). To be able to determine the best treatment option in
each patient, a personalized assessment is necessary, including the evaluation of different
aspects of health, motivation, and availability or access to specific treatments [2].
Profitability is a fundamental aspect when it comes to reviewing treatment options in
this type of condition, which entail great social and financial costs. Previous studies [7]
showed a value of EUR 7 billion in subjects with OAB over 18 years old in Canada and
European countries, including Spain [7].
There are several alternatives for OAB and UI treatment: behavioral treatments,
considered first-line treatments; pharmacological or second-line treatments such as an-
ticholinergic or antimuscarinic and b-adrenergic drugs, and, by way of a third line of
treatment, injections of OnabotulinumtoxinA and therapies with electrical stimulation,
including, among others, percutaneous and transcutaneous electrical stimulation (PTNS
and TTNS, respectively), which are the object of this study [8].
With regard to treatment by electrical stimulation of the posterior tibial nerve (PTN),
this involves retrograde stimulation of the nerve fibers of the sacral plexus, which in-
nervates the bladder and detrusor muscle [2–5,8]. Electrical stimulation can be applied
through insertion of a needle in the PTN—that is, PTNS is carried out in the said nerve—or
through surface electrodes, with TTNS [9], with beneficial and safe effects in the short
term in women with OAB, and no relevant adverse effects [10], according to the review by
Sousa-Fraguas et al., 2020.
These techniques may represent an advantage in treatment of subjects with OAB who
present UI, enabling these difficulties to be solved, as they can be compared favorably to
treatment using antimuscarinic drugs, due to them being less costly [11].
In this respect, the present study aimed to summarize the knowledge available and
conduct a critical analysis of the evidence from randomized controlled clinical trials,
observational studies, systematic reviews, and meta-analyses on the effectiveness of PTNS
and TTNS in the treatment of adults with OAB who present UI.
2. Materials and Methods
This systematic review followed the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guidelines [12]. The protocol was registered in the
International Prospective Register of Systematic Reviews (PROSPERO/NHS)—number: 184809.
2.1. Selection Criteria
Three researchers independently reviewed the articles found. In order to formulate the
objective and the question of the review, the PICOS strategy was used [13] (P—population
or patients; I—intervention; C—comparison; O—outcomes; S—study design), in which
P = (adults with OAB syndrome (OABS) and presence of UI); I = (PTNS and TTNS);
C = (control group that received no intervention or received standard/usual care);
O = (randomized clinical trials (RCTs), descriptive, observational studies, systematic
reviews, and meta-analyses), and S = (randomized controlled clinical trials, descriptive
observational studies, systematic reviews, and meta-analyses). This strategy enabled the
establishment of critical reasoning on the issue [13] and the formulation of the following
question: “What is the existing scientific evidence on the treatment of adults diagnosed as
having OABS with UI through procedures of PTNS versus TTNS?”.
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2.2. Data Sources
The bibliographic search was performed between the months of February and May
2021. The search terms used were percutaneous electric nerve stimulation; transcutaneous
electric nerve stimulation; adult; urinary bladder, overactive; urinary incontinence; tibial
nerve. Two multidisciplinary databases, Scopus and Web of Science (WOS), were used in
the search. The search strategy followed is presented in Table 1.





I. (“Transcutaneous Electric Nerve Stimulation” OR “Therapy, Percutaneous Neuromodulation” OR
“Electrical Neuromodulation, Percutaneous”) AND adult AND (“Urinary Incontinence” OR “Urinary
Bladder, Overactive”) AND (“tibial nerve” OR “Posterior tibial nerve”).
II. (“Transcutaneous electrical nerve stimulation” OR “Transcutaneous tibial nerve stimulation” OR
“transcutaneous stimulation tibial nerve”) AND adult AND (“overactive bladder” OR “detrusor
activity” OR “urinary incontinence”).
III. (“percutaneous tibial nerve stimulation” OR “PTNS”) AND adult AND (“overactive bladder” OR




I. (“Transcutaneous Electric Nerve Stimulation” OR “Therapy, Percutaneous Neuromodulation” OR
“Electrical Neuromodulation, Percutaneous”) AND adult AND (“Urinary Incontinence” OR “Urinary
Bladder, Overactive”) AND (“tibial nerve” OR “Posterior tibial nerve”).
II. (“Transcutaneous electrical nerve stimulation” OR “Transcutaneous tibial nerve stimulation” OR
“transcutaneous stimulation tibial nerve”) AND adult AND (“overactive bladder” OR “detrusor
activity” OR “urinary incontinence”).
III. (“percutaneous tibial nerve stimulation” OR “PTNS”) AND adult AND (“overactive bladder” OR
“detrusor activity” OR “urinary incontinence”).
2.3. Data Collection and Analysis
By way of exclusion criteria: all articles not published in English or Spanish; studies
conducted in patients with neurological diseases or UI exclusively of neurogenic origin;
carried out in children, animals, or patients with an associated underlying pathology;
addressing fecal incontinence; in which treatment was not carried out with PTNS or TTNS
of the PTN, or not aimed at treatment of OAB with UI; narrative or nonsystematic reviews;
all documents not aligned with the research problem. The bibliographic research focused
on all articles published from 2015 to 2020.
In order to obtain reliable, valid results, without them being influenced by bias, the
Physiotherapy Evidence Database scale (PEDro) [14] was used to assess the methodological
quality of the experimental studies, based on the Delphi list [15]. In the same way, the
STROBE declaration [16] was applied for the evaluation of observational-type studies,
and the PRISMA declaration [14] for reviews that followed its criteria in their execution.
Articles that did not exceed the score of five in the PEDro scale [14] or with a score of less
than 11 points in the STROBE declaration [16] were excluded, finally obtaining the articles
chosen for the review.
3. Results
3.1. Literature Search
Figure 1 shows the PRISMA flow chart of this systematic review.
The initial search in the databases gathered a total of 259 articles, 98 from Web of
Science (WOS) and 161 from Scopus.
The initial screening phase produced 130 articles after removing duplicates (n = 129).
Based on the titles and abstracts of the articles, a total of 56 articles were removed.
Then, considering the remaining 74 eligible studies, many were excluded after full-text
reading (n = 47), or because it was not possible to access the full text (n = 3), or for not
passing the methodological quality scale (n = 5).
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Figure 1. Flow chart of this systematic review.
Finally, 19 studies [3–5,17–32] were included. Of these, nine were experimental [3,17–24],
including eight RTCs [3,17–22,24] (Table 2); four were observational studies [5,25–27]
(Table 3), and six were either systematic reviews [4,29,31] or a meta-analysis [28], while
two encompassed both types of studies [30,32] (Table 4).
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Table 2. Characteristics of experimental studies included in the systematic review. Sevilla, ES. 2021.
Author/s Study Design Study Population Sample Size Intervention Follow-Up Randomization
Ramírez-García I., et al.,
2019 [17] RCT OAB and OD
n = 68 (46 W and 22 M) (34 per G)
Mean age (MA): 59.6 ± 27.4 kg.
Symptom duration: 1–56 years
with mean of 5.1.
Grupo A(GA)
(intervention)→ TTNS






Scaldazza C.V., et al.,
2017 [18] RCT W with OAB
n = 60 W (30 per G)
MA: 58.5 years (38–72)











W with OAB, with no
previous PTNS or
anticholinergic treatment
n = 36 W (18 per G)
GA: MA = 57.4 ± 9.5 GB:
MA = 55.8 ± 16.2
GA→PTNS




Abulseoud A., et al.,
2018 [20] RCT
W with OAB and OD, and
behavioral treatment failure
n = 30 W (15 per G)
G 1: MA = 48 ± 16.42
G 2: MA = 48.13 ± 10.80
G 1: TTNS + placebo bottle
identical to G 2.
G 2: TTNS + Trospium
Chloride
8 Weeks 1:1 by random numbertable
Martín-García M. &
Cramptom J. 2019 [3] RCT
W with non-neurogenic OAB
who responded to PTNS
initial treatment of 12 weeks
n = 24 W (12 per G)
G PTNS: MA = 58 ± 10







weeks PTNS), at 6 weeks, 3
m and 6 m
1:1 via sealed, opaque
envelopes with numbered
sequences




M/W with OAB after
treatment with ineffective
conservative therapy
n = 48 (24 multiple sclerosis and
24 Idiopathic OAB)
G 1 (daily treatment):
MA = 46.4(32–73), 18 W/6 M,
20 UI
G 2 (weekly treatment):
MA = 46.9(20–81), 20 W/4 M,
18 UI
TTNS
G 1: 1 session/day
G 2: 1 session/week
12 weeks, with evaluation at
4, 8 and 12 weeks
Stratified method by
sealed envelopes
Welk B., et al., 2020 [22] RCT
W with OAB, neurological
diseases with urinary urgency
with or without UI
n = 50. MA (73%, 22/30); 10%
(3/30) used spontaneous voiding
catheter
G TTNS→ n = 26;
MA = 62 (54–68)




flexion of the big toe
GS→ TTNS. Constant
amplitude
12 weeks 1:1 by random numbergenerator





OAB refractory to 1st line
treatments
n = 74 (52 W/22 M), MA = 56.0
(25.2, 59.8).
49 (66.2%)→ neurogenic OAB
25 (33.8%)→ idiopathic OAB
PTNS + drug 12 weeks Without randomization
Mallman S., et al., 2020
[24] RCT W with OAB
n = 50 (25 per G)




6 weeks Sequence generated in 2 Gby WinPEPI version 11.63
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Table 2. Cont.
Author/s Variables Results Conclusions Adverse Effects andLimitations
Met
Quality
Ramírez-García I., et al.,
2019 [17]
Difference day and night
urination
Mean voiding volume
Number of urgencies and
UI Quality of life
At the beginning/12 weeks. GA: n = 34/GB: n = 34
Differences by protocol: GA: n = 32 /GB: n = 29. Post intervention
differences: GA: n = 34/GB: n = 34. Difference adjustment with 95%
confidence interval
Quality of life I-QoL: GA (21.5 p), GB (22.1 p) (P < 0.001)
Both techniques improve




No serious adverse effects
Study carried out to
measure differences
between groups. High cost.
7/10
Scaldazza C.V., et al.,
2017 [18]
Number of voiding in
24 h
Number of UUI episodes
Nocturia






Number of daily voiding→ GA→ P = 0.0620; GB→
P = 0.0307; Difference between groups (DG)→ P = 0.3758
Number of UUI episodes→GA: P = 0.1293; GB→ P = 0.0009; DG:
P = 0.0251
Nocturia→ GA: P = 0.1683; GB→ P = 0.0201; DG: P = 0.049
Voiding volume→ GA: P = 0.0048; GB→ P = 0.0003; DG:
P = 0.0222
OAB-q SF: 6 items: GA: P = 0.0420; GB: P < 0.0001; DG:
P = 0.0172.
13 items: GA: P = 0.0420; GB: P < 0.0001; DG: P = 0.0295
PPIU-S: GA: P = 0.1014; GB: P = 0.0001; DG P = 0.0459
PGI-I→ GA: P = 0.0415; GB: P = 0.0415





Preyer O., et al., 2015
[19]
Differences in number of
voids in 24 h between
both groups (voiding
diaries).
Number of UI episodes
Quality of life (QoL-VAS)
n = 16 per group
Number of voids→ without significant decrease 1–3 m in both G
(P = 0.13), DGNS (P = 0.96). No significant differences in number at
the beginning and post treatment (P = 0.79)
Quality of life (QoL-VAS)→ depends on the initial values, in GB
mean values are lower than GA in 1–3 m Increase in both G 1 and
3 m, without significant changes (P = 0.07)
Number of UI episodes in 24 hours→ depends on the number
episodes at the beginning of treatment (P = 0.0001). NSDG pre/post




number of UI episodes, but
not in urinary frequency.
PTNS has fewer side effects.
The first 4 weeks mainly
GB→ dry mouth and
dizziness. 9 participants
(3 m)
GA→ pain in puncture area.
3 participants (3 m).
Small sample size and
standard deviations greater
than expected, which could
be due to a type II error; no
blinding
6/10









OABSS→ post-treatment G (P < 0.001) and G 2 (P = 0.024)
IIQ-7→ (G1: P = 0.002; G 2: P = 0.001). Pre- treatment min 50 points
(good quality of life), post-treatment 20 (6 G 1 and 14 G 2).
Pre- treatment→ severe OAB symptoms in 26 patients (12 G 1 and
14 G 2), post-treatment 4 (G 1).
Cystometric volume→ post-treatment (G1: P = 0.026; G 2:
P = 0.001), G 2 (P = 0.034)
TTNS is tolerable and
effective when combined
with Trospium Chloride.
Better results without side
effects.
Without side effects
Limitation: need for another
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Table 2. Cont.








Number of UUI episodes
Severity of symptoms
Quality of life (HRQoL)
Urinary frequency G TTNS→ decreasing from the beginning/6 m:
8.5 (1.9) vs 7.7 (2.8), (P = 0.373).; G PTNS→ during the study
(P = 0.242), increasing from 7.3 (4.7) to
8.7 (2.4) at 6 m P = 0.208.
Number of UUI episodes in 24 h: G TTNS→ (P = 0.900);
G PTNS→ (P = 0.655)
Number of urgency episodes in 24 h: G TTNS→ Friedman test
(P = 0.038). Wilconxon test: significant increase baseline/ 6 Weeks:
1.7 (2.8) vs 3.2 (3.6), (P = 0.044); and baseline/3 m: 1.7 (2.8) vs 2.5 (2.6
(P = 0.011). Without significant changes baseline/6 m: 1.7 (2.8) vs 2.0
(1.4) (P = 0.325); G PTNS→
(P = 0.883)
Severity of symptoms→ G TTNS→ (P = 0.584); G PTNS→
(P = 0.854)
Quality of life HRQoL→ G TTNS→ (P = 0.676); G PTNS→
(P = 0.948)
Application of bilateral
TTNS is an effective and
tolerable treatment for the






TTNS without side effects.
PTNS→ 3 minor episodes
of needle insertion bleeding
(2 participants); 1 episode of
discomfort/ pain over the
needle area
7/10
Seth J.H., et al., 2018
[21]
Quality of life (ICIQ-OAB)
and (ICIQ-LUTqol) Part A
for severity of symptoms
and Part B for patient
discomfort.
3-day voiding diary
→ urinary frequency in
24 h; number of UI
episodes.
Quality of life→ improvements in ICIQ-OAB score and
ICIQ-LUTSqol score between the beginning and during 12 week
treatments in both G.
Daily treatment→ part A - ICIQ-OAB→means improved between
the beginning and 12 weeks from 9.3 (2.5) to 7.5 (3.1)Part B —
ICIQ-OAB→ from 29.6 (8.1) to 25.6 (9.5)
Part A — ICIQ-LUTSqol→ from 51 (12.8) to 44.2 (13.1)
Part B — ICIQ-LUTSqol→ from 130.3 (43.7) to 105.5 (57.8)
Weekly treatment→ part A - ICIQ-OAB→ week 12 from 9.1 (1.9) to
5.9 (1.7)
Part B — ICIQ-OAB→ from 29.7 (5.9) to 19.1 (8.5)
Part A — ICIQ-LUTSqol→ from 44.9 (9.0) to 35.9 (8.8)
Part B — ICIQ-LUTSqol→ from 102.1 (40.1) to 63.9 (42.8)
Urinary frequency in 24 h→ Daily treatment→ from 10.8 to 8.2 at
12 weeks
Weekly treatment→ from 12.2 to 9.5 at 12 weeks
Number of UI episodes→ Daily treatment→ from 2.8 to 1.6 at
12 weeks.
Weekly treatment→ from 2.3 to 0.9 at 12 weeks
Safe treatment. Low
frequency stimulation (1
Hz) improves quality of life
and symptoms of voiding
diaries (daily/weekly)
Neurological patients
respond more frequently to
treatment (65%) versus
patients with idiopathic





treatment or in satisfaction
surveys
5 patients said therapy was




developed skin redness in
the area of stimulation
Limitations: high dropout
rate (in relation to device,
lack of improvement, or
local discomfort)
5/10
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Table 2. Cont.
Author/s Variables Results Conclusions Adverse Effects andLimitations
Met
Quality
Welk B., et al., 2020 [22]
Questionnaire
(PPBC) Compress weight
in 24 h, for UI 3-day
voiding diary→ Urinary
frequency and functional
capacity in 24 h Quality of




PPBC→ 13% (3/24) of sham patients and 15 (4/26) of TTNS
treatment were considered responders (P = 0.77) Marginal mean of
the end of the PPBC score was 3.3 (2.8–3.7) for TTNS vs 2.9 (2.5–3.4)
for simulated (P = 0.30)
Compress weight in 24 h→ NSDG (P = 0.64)
Functional capacity→ NSDG(P = 0.12)
Urinary frequency in 24 h→ NSDG(P = 0.32)
OAB-qSF Questionnaire→ NSDG in symptom discomfort
(P = 0.82) and quality of life (P = 0.29)
NBSS→ NSDG (P = 0.16)
Qualiveen-SF→ NSDG (P = 0.85)
Global assessment of improvement→ NSDG (P = 0.27)
TTNS does not display




With no adverse effects
during the study
Limitation in results










urgency and severity of
UI
64 (86%) completed 12 weeks. Significant improvements at 12 weeks
of treatment in ICIQ-OAB
ICIQ-LUTSqol, change in urinary frequency over 24 h and severity
of UI in bladder diary
G neurogenic VH→ ICIQ-OAB (P = 0.04); ICIQ-LUTSqol (P = 0.05)
[in ICIQ-OAB, odds ratio (IC 95%) 0,93 (0,87, 0,99), P = 0,03], severity
of UI [in bladder diary, odds ratio (IC 95%) 0.05 (0.01, 0.63), P = 0.02]
and QoL [IUTQ-LUTSqol, odds ratio (IC 95%) 0.98 (0.96, 0.99),
P = 0.007] at 12 weeks
PTNS is a possible
alternative treatment in
patients with neurological
disease and with ineffective
or intolerable 1st line
treatment
No adverse effects. 5
patients had mild
discomfort at the needle
insertion area
Lack of blinding, lack of a
placebo or control group,






Mallman S., et al., 2020
[24]
Quality of life: KHQ
Severity of UI: ISI
Discomfort due to OAB
symptoms: OAB-V8
NSDG (P > 0.005)
OAB-V8: (6 weeks P = 0.0019) G TPNS/G transcutaneous sacral
EMS
KHQ e ISI: NSDG
Both therapies are effective
and safe for the treatment of
women with OAB, UUI,
and MUI
No side effects 6/10
W = women; M = men; OAB = Overactive bladder syndrome; OV = overactive detrusor; MA = mean age s; G = Group; PTNS = Percutaneous electrical stimulation of the posterior tibial nerve;
TTNS = Transcutaneous electrical stimulation of the posterior tibial nerve; m = month; EMS = electrical stimulation; BMI = body mass index; UI = Urinary incontinence; PP = Per protocol; PIT = Per
Intention to treat; DG = difference between groups; I- QoL = Urinary Incontinence Quality of Life Scale ;UUI = urgency urinary incontinence; OAB-qSF = Overactive Bladder Questionnaire Short Form;
PPIU-S = Scale Patient Perception on Intensity of Urgency Scale; PGI-I = Patient Global Impressions Scale or Disease Improvement; QoL-VAS = Qol. Visual Analogue Scale; OABSS = Overactive Bladder
Screening Scale; IIQ7 = Incontinence Impact Questionnaire-7; HRQoL = Health Related Quality of Life; ICIQ-OAB = International Consultation on Incontinence Questionnaire Overactive Bladder Module;
ICIQ- LUT = International Consults on Incontinence Lower Urinary Tract Symptoms; ICIQ-LUTSqol = International Consults on Incontinence Lower Urinary Tract Symptoms Quality of Life; PPBC = Patient
Perception of Bladder Condition; NBSS = Neurogenic Bladder Symptom Score; Qualiveen-SF = Short Form of Lower Urinary Tract Dysfunction Impact on Quality of Life; NSDG = non-significant difference
between groups; IC = confidence interval
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Table 3. Characteristics of the observational studies included in the systematic review. Sevilla, ES. 2021.
Author/s Study Design Study Population Sample Size Intervention Follow-Up
Salatzki J., et al., 2019 [25] Cross-sectional(cohort)
Positive response to PTNS
treatments (10–12 weeks)
n = 83 PTNS-SEQ
G 1: n = 28
G 2: n = 24
G 3: n = 31
G 1→ non-responders; no maintenance therapy
G 2→ responders; possibility of maintenance therapy: they
did not do it
G 3→ responders who underwent maintenance therapy
18 weeks
Leroux P.A., et al., 2018 [5] Prospective Idiopathic or refractory OAB toanticholinergic treatment
n = 97 treated with TTNS
20 (21%) M; 77 (79%) W
MA = 58.4 ± 16.6
TTNS 24 m
Moratalla-Charcos L.M.,
et al., 2018 [26]
Pilot study
Prospective
OAB with or without OD/UI,
without success in
pharmacological treatment or
dropout due to adverse effects
n = 45: 38 W and 7 M.
MA = 66.6 ± 10.5 (41–83). OD:
53.3%.
TTNS 12 weeks
Palmer C., et al 2019 [27] Retrospective >65 with idiopathic OAB, aftertreatment with PTNS
n = 52: 23 M (44.3%);
29 W (55.8%).
MA = 75.75 (65 to 93);
BMI = 26.33
(17.4 to 43.9) kg/m2
PTNS 12 weeks
Author/s Variables Results Conclusions Adverse Effects andLimitations
Met
Quality
Salatzki J., et al., 2019 [25]







Groups 2 and 3→ improvements compared to G 1. Patients with
idiopathic or non-neurogenic OAB→ significant improvement vs
neurogenic OAB (P = 0.048).
Group 3→ return to treatment after 39–204 days; significant
improvements in nocturia (ICIQ-LUT, P = 0.036) and voiding diary
(P = 0.046)
To identify variables back to maintenance, (nocturia in 3
days/daytime urinary frequency/ number of UUI episodes), ICIQ-
OAB, ICIQ-LUT→successful to distinguish between
G 2 and 3 (Chi-squared 11.23, P = 0.047)
PTNS-SEQ(P = 0.039)→ + 75% of cases. Increase in the categories
“lack of treatment effect” — greater probability of belonging to G 2.
Alternatives found to treatment of PTNS in PTNS-SEQ: (PTNS
n = 28; PTNS home n = 20; PTNS in medicine clinic n = 20)
12 weeks of PTNS→ safe
and effective treatment for
OAB. A beneficial response
with PTNS in nocturia was
a factor to return to
maintenance. The voiding
diary offers more objective




size; difference in number
of participants between G;
results only applicable to
public health.
21/22








3 (3%) died of unknown cause/10 were lost at follow-up
TTNS persistence and predictive factors→mean
follow-up = 39.3 (25–65) m; mean persistence TTNS 8.3 (1–40 m).
persistence = 12 m/28 patients (29%) e = 18 m/16 patients (16%)
Discontinuity risk factors→ At 3 m = 24 (28,9%) abandonment
TTNS. Baseline score USP-OAB > 11 predictor of early treatment





due to a decrease in efficacy
over time.
No adverse effects or pain
Limitation: loss in
follow-up during the study,
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Table 3. Cont.














n = 39/45(86.6%)→ completed 12 weeks treatment
Significant differences before and after treatment (P < 0.05) in
urinary frequency, nocturia, number of urgency episodes, number of
UUI episodes, maximum voiding volume. OABq-SF: P > 0.05.
Statistically significant differences in GOD vs OAB
Treatment satisfaction→ patients with mellitus diabetes
(P = 0.043), in diabetes W (P = 0.042). In ordinal regression with 4
independent variables: number of vaginal deliveries (P = 0.011);
psychiatric history (P = 0.001) were significant. Group with OD→
better satisfaction by increasing the number of vaginal deliveries
and lower satisfaction for W and patients with diabetes. In ordinal
regression with 3 independent variables: number of vaginal
deliveries
(P = 0.05) was significant
OAB treatment with TTNS
is an effective, safe,
minimally invasive and
well tolerated therapy. In
this study, all variables
improved significantly
compared to baseline.
Adverse effect: mild pain







addition to lack of a control
group
17/22





n = 21 (39%) used combination therapy during PTNS
After PTNS→ 37 patients (70%) reported symptom improvements;
7 used anticholinergic, 6 used ß3 adrenoceptor agonist, 5 received
intravesical injections of onabotulinumtoxnA, and 2 underwent
sacral neuromodulation
Mean old age→ n = 13, 1 or 2 medical comorbidities; n = 10, 3, or 4
medical comorbidities; n = 6 + 5. n = 20 W (69%) used
anticholinergic treatments before PTNS; n = 11 W (38%) used
combination therapy during PTNS
Effectiveness and viability
of the PTNS technique for
the treatment of OAB in
elderly patients is observed,
being able to choose as a
2nd line treatment.




study, small sample size
which could influence the
results. More objective
measures should have been
used to determine the
success of the treatment,




PTNS = Percutaneous electrical stimulation of the posterior tibial nerve; PTNS-SEQ = Percutaneous Tibial Nerve Stimultion Service Evaluation Questionnaire; OAB = overactive bladder syndrome;
TTNS = Transcutaneous electrical stimulation of the posterior tibial nerve; M = Man; W = Woman; UI = urinary incontinence; OD = overactive detrusor; G = group; m = month; BMI = body mass index;
ICIQ-OAB = International Consultation on Incontinence Questionnaire Overactive Bladder Module; ICIQ-LUT = Lower urinary tract symptoms related quality of life questionnaire; UUI = urgency urinary
incontinence; USP = Urinary Symptom Profile questionnaire; USP-OAB = Urinary Symptom profile- overactive bladder; OABQ-SF = Overactive Bladder Questionnaire Short Form; OAB-V8 = Overactive Bladder
8 questions Awareness Tool; GIPS = Global Impression of Patient Satisfaction; EMS = electrical stimulation; OAB-q = Short form Symptom Bother; OABSS = Overactive Bladder Symptom Score; UDI-6 = Urinary
Distress Inventory, Short Form; IIQ-7 = Incontinence Impact Questionnaire; ICIQ-UI SF = International Consultation on Incontinence Questionnaire; LUTS = Lower Urinary tract Symptoms; SNM = sacral
neuromodulation; QoL= Quality of life questionnaire.
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Table 4. Characteristics of the systematic reviews and meta-analyses included in the systematic review. Sevilla, ES. 2021.
Author/s StudyDesign
Number and Design
of Studies Study Participants Inerventions Variables Results Conclusions and Limitations














136 sham or placebo
treatment
More W than M
(10/16 W)



















PTNS therapy is effective for the
short-term treatment of OAB, with
greater efficacy than with sham
treatment, and comparable with
antimuscarinic drugs (but with
fewer adverse effects). However,
multimodal therapy was found to be
more effective
PTNS could be a maintenance
therapy due to its safety and
durability
Dose, duration, frequency, pulse of
PTNS, duration of study follow-up
and demographic characteristics of
the subjects were highly variable in
the studies included







>18 years old with OAB
with MUI
n = 629→ 473 (70%) W
and 176 (28%) M, 16





(10%)→ pelvic floor and
bladder training
9 (4%)→ sacral EMS or
without treatment
Durability: 4–12 weeks (mean:
7.6 ± 3.6). Total number of
sessions 5–90
(mean 21.6 ± 2.3)
30 min/individual session,
except 3 of 20 min.
3 studies with daily
stimulation, 7 studies with
2 times/week and

















All studies observed improvements
with TTNS treatment. It is safe and
tolerable, due to this factor, its low
cost, its ease of application and the
possibility of self-administration by
the patient, more studies are
necessary to show its use as a 2nd
line treatment
Tutolo M., et al.,
2018 [29]
Systematic
review 9 articles, all RCTs
Patients with OAB
treated by SNM or
PTNS
SNM and PTNS
PTNS: 4 RCTs→ 388 patients
PTNS vs Tolterodine→ 3 m
(94% W)
PTNS vs sham therapy→ 3 m
PTNS vs placebo→ 12 weeks
PTNS vs vaginal electrical
stimulation→ 12 weeks
Number of UI episodes
and severity







There are no high-quality studies
able to guide professionals to choose
between different treatments. This
study shows that sacral stimulation
and PTNS are safe and effective.
SNM has more long-lasting effects,
while PTNS needs to have
maintenance treatment
Limitations: number of results due
to the impossibility of evaluator and
patient blinding in the studies




of Studies Study Participants Inerventions Variables Results Conclusions and Limitations










patients who have tried










and PTNS and SNM protocols
Quality of life
Number of UUI









Number of UI episodes
per day→ 7/17
Improvement of 50% or
more in symptoms at
12 weeks→8/17
The three modalities are effective
and better than placebo for OAB
treatment. At 12 weeks, SNM had




Lack of enough data to conduct a
meta-analysis in quality of life,
urgency, UUI episodes/day,
maximum bladder capacity and
nocturia
4 studies rated as high risk of bias in
the category of ’outcome
measurement’ because the
self-report results could have been
influenced by the placebo effect.
Heterogeneity between studies
made it difficult to clarify the results
Veeratterapillav
















PTNS vs sham treatment
Follow-up durability varied
Different inclusion criteria














PTNS safety and other
therapies
PTNS cost
PTNS success changed due to
informed symptoms by the patient
(improvements in frequency and
urgency), clinical evaluations (OAB
and QoL questionnaires, voiding
diary), and observation of
aerodynamic variables. Hence,
treatment was successful between
54.5% and 79.5% at 12 weeks and
15% and 71% in 1–3 years
The studies suggested that PTNS
efficacy is better with anticholinergic
as a unique treatment, but there was
limited evidence of combination
therapy efficacy




of Studies Study Participants Inerventions Variables Results Conclusions and Limitations






28 articles, 12 RCTs
16 observational
studies




30 min PTNS for 12 weeks in
6/2 studies, the rest of studies
had different protocols
PTNS vs Tolterodine




























PTNS therapy was shown to be
effective and safe for OAB treatment
Limitations: heterogeneity of the
studies included, however, a
subgroup analysis was performed to
observe that this factor was due to
the study design. Second, evaluation
of the improvements and success of
the variable was done unconsciously
Severe side effects: the most
common was pain in the puncture
area
RCT = randomized control trial; W = woman; M = man; OD = Overactive detrusor; MA = mean age; G = group; PTNS Percutaneous electrical stimulation of the posterior tibial nerve; TTNS = Transcutaneous
electrical stimulation of the posterior tibial nerve; OAB = overactive bladder syndrome; UI = Urinary Incontinence; MUI = mixed urinary incontinence; UUI = Urgency urinary incontinence; EMS = electrical
stimulation; SNM = sacral neuromodulation.
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3.2. Summary of the Evidence
As for the comparison between PTNS and TTNS therapy, studies were found [3,17] in
which significant changes were observed in the variables of diurnal frequency of urination,
nocturnal frequency of urination, 24-h voiding frequency, mean voided volume, and
number of episodes of UI and UUI in 24 h [17].
When TTNS combined with trospium chloride [20] was compared to placebo, a
decrease in frequency of urination was observed in both groups (p = 0.001 and p= 0.003,
respectively); as to mean voided volume, significant improvements were observed in both
groups, with greater significance in the combined therapy (p = 0.005), although there was a
significant delay in the combined therapy group with regard to the first sensation of a full
bladder [20].
In other studies [23,32], upon combining PTNS with drugs, 35/53 participants com-
pleted the satisfaction survey after treatment, 66% of whom preferred to continue with
maintenance treatment, with a mean interval of 44.4 days (7–155 days) and frequency of
sessions of 1.1 months; attendance was observed if there were symptoms of OAB, while
patients with multiple sclerosis had the possibility of returning [23].
Following this comparative line, one review was found [4] in which TTNS was com-
pared with diverse therapies, including 3/10 studies that compared simulated therapy,
4/10 anticholinergic, 1/10 exercise, 1/10 behavioral, and 1/10 two different stimulation
sites. The three remaining studies compared TTNS with other treatments: extended-
release oxybutynin vs. TTNS + fármacoM; TTNS vs. transcutaneous sacral foramina vs.
combination of the two; bladder and pelvic floor training vs. TTNS.
By contrasting daily or weekly treatment [21] with TTNS, 100% of weekly participants
completed the compliance and experience questionnaire, in comparison to 90.5% of patients
on daily therapy [21]. Although 53% (18) gave as a result a moderate or significant
improvement in symptoms for the global response assessment (GRA), 75% (13/20) of
neurological patients with OAB and 36% (5/14) of patients with idiopathic OAB responded
to the intervention [21].
With respect to adherence to treatment [5,17] with TTNS, one of the studies [5] es-
tablished different reasons for discontinuity (in 70 participants): lack of symptom relief
(70%); difficulty in complying (6%); becoming asymptomatic (8%). However, 16.9% (14) of
patients continued treatment, with a mean follow-up of 39.3 months [5].
Meanwhile, a BMI of obesity (=30 kg/m2) was observed to be the only statistically
significant variable predictive of failure in the response to PTNS (p = 0.002) [27]. Notably,
after PTNS therapy, 66% (19/29) of participants informed of an improvement in their
symptoms [27].
Some of the additional complications to those observed in the analysis of
results [3,19,21,23,26,28,30,32] were urinary tract infections in 10/17 studies (peer com-
parisons revealed that OnabotulinumtoxinA was associated with a greater incidence of
urine infections vs. placebo, sacral neurostimulation (SNS), and PTNS); ranking in order of
fewest infections: first PTNS, second SNS, third placebo, and fourth OnabotulinumtoxinA.
Further, urine retention with a need for intermittent catheterization was found in 11/17,
with peer comparisons showing that OnabotulinumtoxinA was associated with a greater
incidence of retention vs. placebo, SNS, and PTNS; ranking in order of lowest incidence:
first SNM, second placebo, third PTNS, and fourth OnabotulinumtoxinA [30].
4. Discussion
The aim of this systematic review was to analyze the scientific evidence on the treat-
ment of OAB with UI through procedures of PTNS, compared to TTNS, of the PTN.
Nineteen studies were included, which analyze, observe, and compare these therapies with
other methods, such as simulated treatment, placebo, anticholinergic or other drugs, sacral
electrical stimulation, or vaginal electrical stimulation.
Among the studies whose intervention was based mainly on PTNS or TTNS therapy
vs. another therapy, UI presented significant improvement when compared to placebo or
Healthcare 2021, 9, 879 15 of 17
simulated treatment [28,29,31]. Abulseoud A et al. [20] showed a significant improvement
in the number of episodes of UI in combined groups of TTNS and trospium choloride
compared to TTNS for eight weeks [20]. It is worth noting the significant improvements
observed in the review by Veeratterapillay R et al. [31] in UUI after 12 weeks of treatment
and two years of maintenance with PTNS therapy, unlike what was observed by Welk B
et al. [22] in their RCT with PTNS therapy, with no significant differences between TTNS
treatment compared to simulated therapy.
It is worth highlighting the improvements in UI reflected in the systematic review
conducted by Booth J et al. [4], when combining TTNS therapy with pelvic floor exercises
or behavioral treatment, as well as the results observed in the systematic review and meta-
analysis performed by Wang M et al., as regards the reduction in the number of episodes
of UI and UUI per day through PTNS therapy [32].
Apart from two studies analyzed [5,24], parameters related to frequency of urination,
urgency of urination, and nocturia, as well as other symptoms of OAB such as voiding
volume and urodynamic changes were included as variables and presented dissimilar
results between studies.
In a recent study [10] from 2020, significant improvements were observed in the
perception of quality of life of patients treated with TTNS and PTNS, with no differences
between treatments [10].
By focusing on the quality of life observed in the studies analyzed, it is worth high-
lighting that all the experimental studies included provided data on this. Some of these
studies [17,18,21,23] showed significant improvements in quality of life, through diverse
questionnaires, after treatment with PTNS or TTNS, revealing that this improvement in-
creased when TTNS was combined with trospium chloride, although the difference was
not significant [20].
In 2013, Peters KM et al. [11] observed improvements in the quality of life of patients
with OAB who were treated with PTNS, evaluated three years after treatment. In the
present review, PTNS has been seen to present significant differences in quality of life
when compared to vaginal electrostimulation [18], and it has been observed that there are
significant differences in increased quality of life in both neurogenic and non-neurogenic
OAB [23].
As for other parameters, it is worth noting the RCT of de Scaldazza CV et al. [18] in
which significant differences were revealed in terms of the patient’s global perception in
favor of the PTNS technique compared to vaginal electrostimulation.
Leroux PA et al. [5] in their study showed some of the reasons why there is disconti-
nuity in treatment with TTNS therapy, the most prevalent of which, in 70% of cases, was
sufficient relief from symptoms, while in 6% it was due to complications for compliance
with the treatment, and in 8% it was due to a complete reduction of the symptoms and
becoming asymptomatic [5].
Most of the studies included in this review report of the absence of adverse effects
during treatment [5,17,18,20,22,24,25]. Studies that combine PTNS and TTNS therapy [17],
and those in which TTNS therapy is involved [5,20,22,25], point out that there are no
adverse effects after the use of this therapy, except for the study conducted by Moratalla-
Charcos LM et al. [26], who speak of mild pain on plantar flexion after the use of this
technique.
Regarding PTNS therapy, no serious adverse effects were found, only minor bleed-
ing episodes were mentioned or mild discomfort at the needle insertion site [3,25,29],
sometimes causing hematomas or paresthesia at the puncture site [31].
As for the electrical stimulation parameters with PTNS therapy, most studies referred
to weekly sessions for 12 weeks as the time of treatment. Although some of them did not
show the other parameters, the rest coincided with regard to sessions of 30 min duration,
a frequency of 20 Hz, pulse of 200 ms, 34-gauge needle inserted approximately five cm
above the medial malleolus, and electrode in ipsilateral calcaneus [17,19,22,23,27]. In terms
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of amplitude, this was increased to the level of discomfort of the patient, feeling of tickling
on the sole of the foot, or flexion of the big toe.
Upon referring to treatment with TTNS therapy, the parameters between the studies
are more variable: some of the studies mentioned the same stimulation parameters as those
of PTNS therapy, while others varied in terms of frequency, using a frequency of 10 Hz,
as was the case of the randomized clinical trial of Welk B et al. [22], also highlighting the
frequency of weekly sessions, with a total of three weekly sessions for 12 weeks.
The experimental studies of Abulseoud A et al. [20] and Seth JH et al. [21] stand out
due to the use of different parameters, with the former [20] using frequencies of 10 Hz,
pulse of 250 ms, treatment three times a week for eight weeks, and with a stimulation
time of 30 min. Meanwhile, in the latter study [21], they used amplitudes of 27 mA, pulse
between 70 and 560 ms, which varied depending on patient tolerability, for 12 weeks, both
daily and weekly. Mallman S et al. [24], in their RCT, showed a stimulus duration of 20 min
with a follow-up of six weeks and a pulse duration of 300 ms.
5. Conclusions
It is complicated to be able to establish which electrical stimulation therapy of the
PTN is the most effective for treatments of idiopathic OAB with UI in adults, as far as the
different parameters observed in this review are concerned, due to the variability of the
results obtained and the electrical stimulation parameters used in the studies included.
Nevertheless, it is worth highlighting the advantages TTNS therapy presents with respect
to PTNS therapy, as this could be more comfortable for the patient, all things being equal
in the results variable.
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